Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel Free CLVR Stock Alerts

Clever Leaves (CLVR) Competitors

Clever Leaves logo
Compare

CLVR vs. VINC, SCPS, NAVB, EVLO, and GNCA

Should you buy Clever Leaves stock or one of its competitors? Clever Leaves's main competitors and comparable companies include Vincerx Pharma (VINC), Scopus BioPharma (SCPS), Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), and Genocea Biosciences (GNCA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Clever Leaves compare to Vincerx Pharma?

Vincerx Pharma (NASDAQ:VINC) and Clever Leaves (NASDAQ:CLVR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

Clever Leaves has higher revenue and earnings than Vincerx Pharma. Vincerx Pharma is trading at a lower price-to-earnings ratio than Clever Leaves, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vincerx PharmaN/AN/A-$40.16M-$5.31N/A
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A

Clever Leaves' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Vincerx PharmaN/A -248.33% -132.73%
Clever Leaves N/A N/A N/A

44.0% of Vincerx Pharma shares are owned by institutional investors. Comparatively, 6.9% of Clever Leaves shares are owned by institutional investors. 15.6% of Vincerx Pharma shares are owned by company insiders. Comparatively, 8.2% of Clever Leaves shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Vincerx Pharma's average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company Overall Sentiment
Vincerx Pharma Neutral
Clever Leaves Neutral

Vincerx Pharma has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market. Comparatively, Clever Leaves has a beta of 3816.13, suggesting that its stock price is 381,513% more volatile than the broader market.

Summary

Clever Leaves beats Vincerx Pharma on 6 of the 9 factors compared between the two stocks.

How does Clever Leaves compare to Scopus BioPharma?

Clever Leaves (NASDAQ:CLVR) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

6.9% of Clever Leaves shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Scopus BioPharma N/A N/A N/A

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Clever Leaves Neutral
Scopus BioPharma Neutral

Scopus BioPharma has lower revenue, but higher earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

Clever Leaves has a beta of 3816.13, suggesting that its stock price is 381,513% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.19, suggesting that its stock price is 119% less volatile than the broader market.

Summary

Clever Leaves beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.

How does Clever Leaves compare to Navidea Biopharmaceuticals?

Clever Leaves (NASDAQ:CLVR) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Navidea Biopharmaceuticals has lower revenue, but higher earnings than Clever Leaves.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

Company Net Margins Return on Equity Return on Assets
Clever LeavesN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Clever Leaves Neutral
Navidea Biopharmaceuticals Neutral

6.9% of Clever Leaves shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 8.2% of Clever Leaves shares are held by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Clever Leaves has a beta of 3816.13, meaning that its share price is 381,513% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market.

Summary

Clever Leaves beats Navidea Biopharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Clever Leaves compare to Evelo Biosciences?

Evelo Biosciences (NASDAQ:EVLO) and Clever Leaves (NASDAQ:CLVR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

0.3% of Evelo Biosciences shares are owned by institutional investors. Comparatively, 6.9% of Clever Leaves shares are owned by institutional investors. 1.0% of Evelo Biosciences shares are owned by insiders. Comparatively, 8.2% of Clever Leaves shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Clever Leaves has higher revenue and earnings than Evelo Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A-$114.53M-$4.21N/A
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A

Company Net Margins Return on Equity Return on Assets
Evelo BiosciencesN/A N/A N/A
Clever Leaves N/A N/A N/A

In the previous week, Evelo Biosciences' average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company Overall Sentiment
Evelo Biosciences Neutral
Clever Leaves Neutral

Evelo Biosciences has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market. Comparatively, Clever Leaves has a beta of 3816.13, suggesting that its stock price is 381,513% more volatile than the broader market.

Summary

Clever Leaves beats Evelo Biosciences on 6 of the 7 factors compared between the two stocks.

How does Clever Leaves compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and Clever Leaves (NASDAQ:CLVR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

0.6% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 6.9% of Clever Leaves shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by insiders. Comparatively, 8.2% of Clever Leaves shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Clever Leaves has higher revenue and earnings than Genocea Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Clever Leaves$17.42M0.00-$17.90M-$12.36N/A

Clever Leaves' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Clever Leaves N/A N/A N/A

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Clever Leaves Neutral

Genocea Biosciences has a beta of 1.61, meaning that its share price is 61% more volatile than the broader market. Comparatively, Clever Leaves has a beta of 3816.13, meaning that its share price is 381,513% more volatile than the broader market.

Summary

Clever Leaves beats Genocea Biosciences on 8 of the 9 factors compared between the two stocks.

Get Clever Leaves News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLVR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLVR vs. The Competition

Export
MetricClever LeavesPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$18K$11.86B$7.06B$13.10B
Dividend YieldN/A2.70%2.57%10.45%
P/E Ratio0.00775.15269.0625.28
Price / SalesN/A743.25601.6191.31
Price / CashN/A66.4570.4850.90
Price / BookN/A11.6012.916.24
Net Income-$17.90M$2.76B$3.45B$347.60M

Clever Leaves Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLVR
Clever Leaves
N/AN/AN/AN/A$18K$17.42MN/A560
VINC
Vincerx Pharma
N/A$0.01
flat		N/A-67.6%$66KN/AN/A60
SCPS
Scopus BioPharma
N/A$0.00
flat		N/A-66.7%$17KN/AN/A9
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
EVLO
Evelo Biosciences
N/AN/AN/AN/A$6KN/AN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CLVR) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel